| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.6 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | -0.035 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |